Durvalumab in the treatment of locally advanced unresectable non‑small cell lung cancer – case report

Abstract

At the moment, almost every fourth patient with non-small cell lung cancer is in clinical stage III at the time of diagnosis and, unfortunately, more often with the impossibility of radical resection. Despite curative standard chemotherapy with radiotherapy, the disease relapses in most patients.

Immunotherapy with durvalumab has become a hope for these patients, as evidenced by our case report.

Keywords

• non-small cell lung cancer
• durvalumab